The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pamrevlumab plus nab-paclitaxel/gemcitabine (Pam + GA) as first- and second-line therapy in metastatic pancreatic cancer (mPDAC): Results from Precision Promise (PrP) Bayesian platform trial.
 
Vincent Picozzi
Stock and Other Ownership Interests - Amgen; Cigna; Iovance Biotherapeutics; Johnson & Johnson; McKesson; Thermo Fisher Scientific
Consulting or Advisory Role - TriSalus Life Sciences
Research Funding - Abbvie; Amal Therapeutics; Astellas Amgen BioPharama; FibroGen; Ipsen; NGM Biopharmaceuticals; Novocure
 
Anna Varghese
Consulting or Advisory Role - AstraZeneca (I); Lilly (I); PAIGE (I); Roche (I)
Research Funding - BioMed Valley Discoveries; Bristol-Myers Squibb; Illumina (I); Lilly; Silenseed; Verastem
Travel, Accommodations, Expenses - Roche (I)
 
Paul Oberstein
Consulting or Advisory Role - Amal Therapeutics; AstraZeneca; Ipsen; Janssen Oncology; Loxo/Lilly
Speakers' Bureau - AstraZeneca
Research Funding - Amal Therapeutics (Inst); Arcus Biosciences (Inst); Merck (Inst); Novartis (Inst); Roche/Genentech (Inst); Zai Lab (Inst)
Expert Testimony - Ipsen
Travel, Accommodations, Expenses - Merck
 
Manuel Hidalgo
Leadership - BMS
Stock and Other Ownership Interests - Champions Oncology; InxMed; Nelum Corp.
Honoraria - Champions Oncology; InxMed; MiNK Therapeutics; Oncomatrix
Consulting or Advisory Role - Fibrogen; InxMed; KAHR Medical; MiNK Therapeutics; Oncomatrix
Research Funding - Ranok Therapeutics; TopAl
Patents, Royalties, Other Intellectual Property - Royalties from Khar Medical for IP in cell therapy; Royalties from Myriad for PALB2 patent
Travel, Accommodations, Expenses - Agenus
 
Brian Wolpin
Consulting or Advisory Role - Agenus; EcoR1 Capital; GRAIL; Ipsen; Mirati Therapeutics; Revolution Medicines; Third Rock Ventures
Research Funding - AstraZeneca (Inst); Harbinger Health (Inst); Lilly (Inst); Novartis (Inst); Revolution Medicines (Inst)
 
Kian-Huat Lim
Honoraria - CURIS
Patents, Royalties, Other Intellectual Property - Hold patent for targeting MK2 as a therapeutic strategy in pancreatic cancer.
 
Anna McGlothlin
Consulting or Advisory Role - Berry Consultants
Research Funding - Berry Consultants
 
Todd Graves
Consulting or Advisory Role - Berry Consultants
Research Funding - Berry Consultants
 
Michelle Detry
Employment - Berry Consultants
Consulting or Advisory Role - Berry Consultants
 
Mark Fitzgerald
Consulting or Advisory Role - Berry Consultants
Research Funding - Berry Consultants
 
Anna Bosse
Consulting or Advisory Role - Berry Consultants
Research Funding - Berry Consultants
 
Cassadie Moravek
Consulting or Advisory Role - Novartis (Inst)
Other Relationship - Abbvie (Inst); FibroGen (Inst); Novartis (Inst); TYME (Inst)
 
Samantha Pedersen
No Relationships to Disclose
 
Anna Berkenblit
Employment - Immunogen; Pancreatic Cancer Action Network
Leadership - Immunogen; Nested; Surrozen
Stock and Other Ownership Interests - Immunogen; Nested; Surrozen
 
Jian Chen
Employment - FibroGen
Stock and Other Ownership Interests - FibroGen
 
Ewa Carrier
Employment - FibroGen
Stock and Other Ownership Interests - FibroGen
Consulting or Advisory Role - Calidi Biotherapeutics
Research Funding - FibroGen
Patents, Royalties, Other Intellectual Property - FibroGen
 
Deyaa Adib
Employment - FibroGen
Leadership - FibroGen
 
Donald Berry
Employment - Berry Consultants
Leadership - Berry Consultants
Stock and Other Ownership Interests - Berry Consultants
Consulting or Advisory Role - Berry Consultants
Travel, Accommodations, Expenses - Berry Consultants
 
Diane Simeone
Leadership - Immodulon; Immunovia
Stock and Other Ownership Interests - Longevity Life Advisors
Honoraria - Pfizer
Consulting or Advisory Role - FibroGen
Research Funding - Biological Dynamics; Clearnote Health; Immunovia; Micronoma
Patents, Royalties, Other Intellectual Property - small royalties for my patent on pancreatic cancer stem cells also I receive an annual royalty for a textbook I edited Greenfields Textbook of Surgery
 
Andrew Ko
Honoraria - Medscape; MJH Life Sciences; Research to Practice
Consulting or Advisory Role - AADi; Arcus Biosciences; Eisai; FibroGen; Genentech; GRAIL; Merus; Roche/Genentech
Research Funding - AbGenomics International (Inst); Apexigen (Inst); Astellas Pharma (Inst); BioMed Valley Discoveries (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); CrystalGenomics (Inst); Genentech/Roche (Inst); Leap Therapeutics (Inst); Merck (Inst); Verastem (Inst)